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Statement of translational relevance.
The identification of key regulators of apoptosis in advanced melanoma may provide new therapeutic targets to improve efficacy of anti-tumor agents that activate the intrinsic or the extrinsic apoptosis pathways. We found that melanoma susceptibility to apoptosis by 
Introduction
Advanced melanoma is an aggressive disease hardly curable by currently available treatments (1) . Different genetic alterations in this tumor fuel the constitutive activation of the mitogen-activated protein kinases (MAPK) and phosphoinositide 3-kinase (PI3K)-AKTmTOR pathways (2) , which, in turn, promote resistance to cell death regulated by the intrinsic and extrinsic pathways of apoptosis (3, 4) . Targeted therapy aimed at inhibiting one of these intracellular signaling pathways (5) has indeed shown highly significant clinical results in metastatic patients, as demonstrated by a phase III trial with a BRAFV
600E
-specific inhibitor (6) . Interestingly BRAF
V600E
-selective inhibitors, as PLX4720, may contribute to promote/rescue melanoma susceptibility to apoptosis (7, 8) .
However, melanomas can show primary (9, 10) or acquired resistance to BRAF inhibitors (see ref.
11 for review), suggesting that targeting of a single signaling pathway may not be sufficient in all instances for blocking melanoma growth and rescuing susceptibility to apoptosis. To achieve such result, potentially effective strategies include the combinatorial usage of inhibitors of different signaling pathways (12) or the identification and targeting of key regulators of melanoma resistance to apoptosis (13) . The latter strategy may improve the anti-tumor efficacy of currently available treatments, including targeted therapy or even conventional chemotherapy (see ref.1 for review). To this end, in this study we investigated the expression in melanoma cells, and role in apoptosis, of the inhibitor of apoptosis protein (IAP) Apollon/BIRC6 (14) (15) (16) . Apollon, a 528 kDa membrane-associated IAP, inhibits the mitochondrial pathway of apoptosis by promoting ubiquitination and degradation of the proapoptotic molecule Smac/DIABLO and of caspase-9 (14, 15) . In addition, Apollon depletion promotes p53 stabilization leading to caspase-2-and -3-dependent apoptosis (16, 17) .
Although the expression of several IAPs in melanoma and their role in chemoresistance have been previously investigated (18) (19) (20) , the potential role of Apollon in regulating melanoma 5 cell apoptosis activated by the intrinsic and/or extrinsic pathways of programmed cell death needs to be clarified.
The results indicated that Apollon plays a relevant role in melanoma resistance to apoptosis by anti-tumor agents that trigger the intrinsic or the extrinsic apoptosis pathways.
Furthermore, the results suggest that this IAP may be evaluated as a potentially relevant therapeutic target, to improve the efficacy of currently available pharmacological treatments of melanoma. (Fig. 1A) . Western blot analysis in cell lines representative of different genetic backgrounds (in terms of BRAF or NRAS oncogene mutations) confirmed expression of Apollon and of other IAPs (Fig. 1B) .
The level of expression of Apollon and other IAPs was not significantly associated with the presence of mutated BRAF or NRAS oncogenes in the cell lines (Fig. 1C, P>0 .05 for all four IAPs by ANOVA followed by Bonferroni post-test), nor with the p53 status (data not shown). By immunohistochemistry in surgical samples, Apollon was found expressed in melanoma cells in-vivo, although with variable levels of staining intensity in different tumors ( Fig. 1D and Supplementary Fig. 1 ), or even within the same lesion (see insets Fig. 1D and Supplementary Fig. 1 ). Apollon expression in benign melanocytic lesions was weaker than in melanomas (Fig. 1E) . with apoptosis only by PLX4720 and fotemustine, but not by PD0325901 (Supplementary Table 1 ).
Melanoma apoptosis correlates with downmodulation of
In contrast, other BRAF V600E mutant melanoma cell lines that were resistant to apoptosis by these agents did not show Apollon downmodulation ( significantly inhibited by lactacystin treatment, associated with reduced apoptosis (Fig. 4B,   C ). These results suggested that Apollon downmodulation, promoted by different anti-tumor agents, is caspase-independent and proteasome-dependent.
Apollon silencing enhances melanoma cell death in response to cytotoxic drugs, to MEK and BRAF V600E inhibitors and to soluble or membrane-bound TRAIL. To directly assess the role of Apollon in melanoma apoptosis, we carried out Apollon silencing experiments by siRNA. Two siRNAs (#2 and #4) were evaluated in the initial studies (Fig.   5A ), and siRNA#4 was selected for subsequent studies. Apollon protein expression was inhibited at 24-96 hours by the specific siRNA, as detected by Western blot and flow cytometry ( Fig. 5A and 5B), while c-IAP1 and c-IAP2 were not affected ( Fig. 7 ), as well as in response to cytotoxic drugs as camptothecin or celecoxib ( Supplementary Fig. 8 ). As expected, based on apoptosis assays (already shown in Mitochondria depolarization, an early step in the apoptosis cascade induced by Apollon silencing, was not affected by the pan-caspase inhibitor z-VAD-fmk (Fig. 6D) . Instead, the same inhibitor, but not the negative control z-FA-fmk, significantly reduced cell death induced by Apollon silencing and by its combination with PD0325901 (Fig. 6E) .
Overall, these data indicate that Apollon silencing increases expression of pro-apoptotic Bcl-2 family members, promotes mitochondria depolarization and activation of caspase-dependent apoptosis.
Apollon silencing alters the profile of genes modulated by anti-tumor agents. To test the effects of Apollon silencing on genes modulated by anti-tumor agents we used whole genome microarray analysis of melanoma cells (Me23682) bearing expressed vs. silenced Apollon and treated with PD0325901 or PLX4720. Two major clusters of significantly upregulated and downregulated genes were associated with inhibitor treatment, and not with Apollon silencing (Supplementary Fig. 9A ). Almost all of the most modulated genes by either inhibitor (i.e. those with a fold change >2) were not significantly affected by concurrent Apollon silencing, as indicated by correlation analysis (Supplementary Fig. 9 ).
However, pairwise significance analysis of modulation of each of these genes showed a few notable exceptions (gene symbols in bold, color in Supplementary Fig. 9B Fig. 9B ).
We then classified, by Venn diagrams, all genes with significant modulation by any of the treatments, but irrespective of FC ( Supplementary Fig. 10A and Supplementary Fig. 11A for PD0325901 and PLX4720, respectively). By Ingenuity Pathway Analysis on genes defined by these Venn diagrams we found that Apollon silencing did alter the profiles of genes modulated by PD0325901 and PLX4720 and belonging to several functional classes (listed in Supplementary Fig. 10B and 11B) . This was also shown by IPA analysis of genes modulated only by the combination of drug treatment and Apollon silencing ( Supplementary   Fig. 10 C,D and 11 C,D) . Detailed analysis of the latter set of genes showed that the majority had a FC <1.5, but a minority showed a FC between 1.5 and 2 ( Supplementary Fig. 12) . Many of the genes with a FC >1.6 had direct or indirect functions related to either apoptosis and/or regulation of proliferation and cell cycle control (gene symbols in bold, underlined in Supplementary Fig. 12 ).
Taken together, these results suggest that Apollon knockdown may contribute to the anti-tumor effects of inhibitors as PD0325901 and PLX4720 even by altering the overall profile of genes modulated by such anti-tumor agents. 
Discussion
The present study indicates that Apollon is constitutively expressed in human melanoma cells in-vitro and in-vivo, and is a relevant factor in melanoma cell resistance to cell death activated by agents that trigger the intrinsic and extrinsic pathways of apoptosis.
We found a significant correlation between extent of melanoma cell death and extent of Apollon downmodulation induced by cytotoxic agents, signaling pathway inhibitors and HLA class II ligation through a specific mAb. These findings suggest that melanoma apoptosis in response to anti-tumor agents is critically dependent on downmodulation of this IAP. 
